International Journal of Hematology

, Volume 92, Issue 5, pp 762–764

Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients

  • Kenji Ishitsuka
  • Hiroo Katsuya
  • Tomona Toyota
  • Masanao Ishizu
  • Naoko Kunami
  • Mana Fujita
  • Hidenori Sasaki
  • Yasushi Takamatsu
  • Masanobu Uchiyama
  • Haruo Fujikane
  • Kentaro Ogata
  • Shuuji Hara
  • Kazuo Tamura
Case Report

Abstract

Combination therapy with interferon-α and zidovudine (IFN/AZT) has been regarded as standard care for acute and indolent (i.e., chronic and smouldering) ATL based on reports involving a limited number of patients. This treatment approach has not been evaluated in Japan, a major endemic area of this disease in the world. This is the first Japanese report of IFN/AZT for ATL. It is impossible to draw any definitive conclusion from this small study; however, IFN/AZT showed clear anti-ATL effects for refractory/relapsed ATL patients. This report would contribute for developing future ATL treatment in Japan.

Keywords

ATL Interferon Zidovudine 

References

  1. 1.
    Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol. 2008;80:185–96.CrossRefPubMedGoogle Scholar
  2. 2.
    Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3:276–82.CrossRefPubMedGoogle Scholar
  5. 5.
    Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Matsushita K, Arima N, Yamaguchi K, Matsumoto T, Ohtsubo H, Hidaka S, et al. Granulocyte colony-stimulating factor production by adult T-cell leukaemia cells. Br J Haematol. 2000;111:208–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Macnab KA, Gill MJ, Sutherland LR, De Boer Visser N, Church D. Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother. 1993;31:421–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Bazarbachi A, Plumelle Y, Ramos JC, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177–83.Google Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Kenji Ishitsuka
    • 1
  • Hiroo Katsuya
    • 1
  • Tomona Toyota
    • 1
  • Masanao Ishizu
    • 1
  • Naoko Kunami
    • 1
  • Mana Fujita
    • 1
  • Hidenori Sasaki
    • 1
  • Yasushi Takamatsu
    • 1
  • Masanobu Uchiyama
    • 2
  • Haruo Fujikane
    • 2
  • Kentaro Ogata
    • 3
  • Shuuji Hara
    • 3
  • Kazuo Tamura
    • 1
  1. 1.Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka UniversityFukuokaJapan
  2. 2.Department of PharmacyFukuoka University HospitalFukuokaJapan
  3. 3.Faculty of Pharmaceutical SciencesFukuoka UniversityFukuokaJapan

Personalised recommendations